secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2026-08-13T20:07:45+00:00
Accession:  0001437749-26-027667
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q2 2026 net income $1.8M, revenue up 11.5% to $7.2M
------------------------------------------------------------

- Net income $1.8M ($0.20 diluted EPS) vs $0.5M ($0.06) in Q2 2025; adjusted EBITDA $2.7M vs $1.4M.
- Product sales $7.2M, +11.5% YoY; gross margin fell to 33.9% from 43.7% on lower volumes and quality scrap.
- Received $2M legal settlement from former Re-Tain contract manufacturer, boosting net income.
- Cash rose to $8.9M from $3.8M at year-end; working capital $16.6M, equity $31.4M.
- Plans ~$3.5M freeze-drying capacity (H1 2027) and ~$4.5M liquid processing expansion; aims to triple capacity in 18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774926027667/0001437749-26-027667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774926027667/iccc20260808_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-027667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer